The ejection fraction is an important measurement in determining how well the heart is pumping out blood and in diagnosing and tracking heart failure. About half of patients with heart failure have a preserved ejection fraction (HFpEF), also known as diastolic heart failure, while the others display a reduced ejection fraction (HFrEF), also referred to as systolic heart failure. Clinical trials have shown that treatments improve outcomes for patients with HFrEF but not those with HFpEF. Therefore, interventions designed to prevent HFpEF might be more effective to reduce the global disease burden. To better inform strategies to prevent HFpEF (and HFrEF), detailed insight is needed into disease-specific risk factors. With this goal in mind, researchers recently examined the associations of 12 cardiovascular biomarkers with HFpEF and HFrEF. The findings suggest that traditional cardiovascular biomarkers are primarily associated with HFrEF, highlighting the need for further studies focused on elucidating drivers of HFpEF. The study, which was published in JAMA Cardiology, was partly funded by NHLBI.